The American Renal Associates Holdings Inc. (ARA) Downgraded by Zacks Investment Research to “Sell”

The American Renal Associates Holdings Inc. (ARA) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research downgraded shares of American Renal Associates Holdings Inc. (NYSE:ARA) from a hold rating to a sell rating in a report issued on Tuesday.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

A number of other equities analysts have also recently issued reports on ARA. Leerink Swann restated a buy rating on shares of American Renal Associates Holdings in a research report on Thursday, August 11th. Wells Fargo & Co. restated a buy rating on shares of American Renal Associates Holdings in a research report on Sunday, September 25th. Barclays PLC restated a buy rating and issued a $31.00 price objective on shares of American Renal Associates Holdings in a research report on Thursday, August 18th. Finally, Bank of America Corp. restated a buy rating and issued a $35.00 price objective on shares of American Renal Associates Holdings in a research report on Monday, August 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $31.17.

American Renal Associates Holdings (NYSE:ARA) opened at 17.58 on Tuesday. American Renal Associates Holdings has a 52-week low of $17.43 and a 52-week high of $29.65. The company’s market capitalization is $542.66 million. The stock has a 50 day moving average price of $19.59 and a 200 day moving average price of $24.43.

American Renal Associates Holdings (NYSE:ARA) last issued its earnings results on Tuesday, August 9th. The company reported ($0.75) EPS for the quarter. The company had revenue of $185.60 million for the quarter, compared to the consensus estimate of $161.50 million. Analysts anticipate that American Renal Associates Holdings will post $0.95 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC bought a new stake in shares of American Renal Associates Holdings during the second quarter worth $130,000. American International Group Inc. bought a new stake in shares of American Renal Associates Holdings during the second quarter worth $146,000. Nationwide Fund Advisors bought a new stake in shares of American Renal Associates Holdings during the second quarter worth $166,000. Rhumbline Advisers bought a new stake in shares of American Renal Associates Holdings during the second quarter worth $225,000. Finally, Alambic Investment Management L.P. bought a new stake in shares of American Renal Associates Holdings during the second quarter worth $229,000. 85.20% of the stock is currently owned by hedge funds and other institutional investors.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Related posts

Leave a Comment